US Patent 11236121 Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid
Patent 11236121 was granted and assigned to SAGE Therapeutics on February, 2022 by the United States Patent and Trademark Office.
Currently, there are no issues on this topic.
Find more entities like US Patent 11236121 Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
